Your browser doesn't support javascript.
loading
Central line-associated Rhizobium radiobacter bloodstream infection in two allogeneic hematopoietic cell transplant recipients.
Hartman, Rachel E; Freyer, Craig W; Athans, Vasilios; McCurdy, Shannon R; Frey, Noelle V.
Afiliação
  • Hartman RE; Department of Pharmacy, 21798Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
  • Freyer CW; Department of Pharmacy, 21798Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
  • Athans V; Department of Pharmacy, 21798Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
  • McCurdy SR; Blood and Marrow Transplantation Program, Abramson Cancer Center and the Division of Hematology and Oncology, 21798Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
  • Frey NV; Blood and Marrow Transplantation Program, Abramson Cancer Center and the Division of Hematology and Oncology, 21798Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
J Oncol Pharm Pract ; : 10781552231161826, 2023 Mar 14.
Article em En | MEDLINE | ID: mdl-36919273
INTRODUCTION: Rhizobium radiobacter is a gram-negative, opportunistic phytopathogen that rarely causes human infections. We report two cases of Rhizobium radiobacter central line-associated bloodstream infection (CLABSI) in allogeneic hematopoietic cell transplantation (alloHCT) recipients. We review previous reports and common microbiological characteristics associated with this organism. CASE REPORTS: Two adult males developed R. radiobacter CLABSIs at day +81 and day +77 post-alloHCT. Patient one was asymptomatic on presentation while patient two was febrile. One patient had a polymicrobial infection, which has not been previously described. The presence of high-level ceftazidime resistance in both patients suggests third-generation cephalosporin resistance may be more common than previously recognized. MANAGEMENT AND OUTCOME: For both patients, microbiologic clearance was achieved through peripherally inserted central catheter removal and initiation of intravenous cefepime. Antibiotic therapy was narrowed to oral levofloxacin for a total 14-day course from the time of first negative blood culture. There has been no subsequent recurrence of R. radiobacter infection at 12 and 5 months of follow-up for patients one and two, respectively. DISCUSSION: These two cases add to the scant literature characterizing R. radiobacter infection following alloHCT. Immunosuppressive agents for graft-versus-host disease prophylaxis may have predisposed these patients to R. radiobacter infection. Our reports, and previously reported cases, suggest R. radiobacter exhibits low virulence, mild symptom burden, and does not confer a high mortality risk. In the alloHCT setting, further accumulation of cases is needed to aid in understanding clinical features and characteristics of R. radiobacter infection.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: J Oncol Pharm Pract Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: J Oncol Pharm Pract Ano de publicação: 2023 Tipo de documento: Article